US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

12.87 +0.11 (+0.86%)
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Forecasting The Future: 5 Analyst Projections For Arcturus Therapeutics ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock ↗
 
Via Benzinga
News headline image
Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gildan Activewear And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Tuesday's session ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Arcturus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
From Arcturus Therapeutics
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Monday? ↗
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 6, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >